IJTLD open最新文献_第8页

A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020. 2009-2020 年乌兹别克斯坦耐异烟肼结核病管理十年回顾。

IJTLD open Pub Date : 2024-07-01 DOI: 10.5588/ijtldopen.23.0533

M L Rekart, P Thit, M Oluya, S Moe, T Hasan, N Parpieva, K Safaev, A Khristusev, T Zinaida, J Singh, S Allamuratova, I Azamat, C G Restrepo, N Sitali, J Achar, J L Alvaraez, A Sinha

{"title":"A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020.","authors":"M L Rekart, P Thit, M Oluya, S Moe, T Hasan, N Parpieva, K Safaev, A Khristusev, T Zinaida, J Singh, S Allamuratova, I Azamat, C G Restrepo, N Sitali, J Achar, J L Alvaraez, A Sinha","doi":"10.5588/ijtldopen.23.0533","DOIUrl":"10.5588/ijtldopen.23.0533","url":null,"abstract":"Background: Isoniazid (INH, H) resistance is the most common drug-resistant TB pattern, with treatment success rates lower than those in drug-susceptible TB. The WHO recommends a 6-month regimen of rifampicin (RIF, R), ethambutol (EMB, E), pyrazinamide (PZA, Z), and levofloxacin (Lfx) (6REZLfx) for INH-resistant, RIF-susceptible TB (HRRS-TB). Uzbekistan has a high burden of TB (62/100,000 population) and multidrug-resistant TB (12/100,000 population).Methods: We conducted a retrospective, descriptive study of microbiologically confirmed HRRS-TB using routinely collected programmatic data from 2009 to 2020.Results: We included 854 HRRS-TB cases. Treatment success was 80.2% overall. For REZLfx, the treatment success rate was 92.0% over a short treatment duration, with no amplifications to RIF or second-line anti-TB drug resistance. We documented 46 regimens with REZLfx plus linezolid (success 87.0%) and 539 regimens using kanamycin or capreomycin (success 76.6%). We identified 37 treatment failures (4.3%), 30 deaths (3.5%), 25 resistance amplifications (2.9%), including eight to RIF (0.9%), and 99 lost to follow-up (LTFU) cases (11.6%). Unsuccessful outcomes were more common with older age, diabetes, chest X-ray cavities, smear positivity, smear-positive persistence, and male sex. LTFU was more common with injection-containing regimens.Conclusions: REZLfx is a safe and effective first-line treatment for INH-resistant, RIF-susceptible TB. Treatment success was lower and LTFU was higher for injection-containing regimens.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"1 7","pages":"285-291"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11257092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence and predictors of NTM in presumed/confirmed drug-resistant TB. 推定/确诊耐药性肺结核中 NTM 的流行率和预测因素。

IJTLD open Pub Date : 2024-07-01 DOI: 10.5588/ijtldopen.24.0242

E T Abbew, R Laryea, F Sorvor, Y A Poku, N Lorent, D Obiri-Yeboah, L Lynen, L Rigouts

{"title":"Prevalence and predictors of NTM in presumed/confirmed drug-resistant TB.","authors":"E T Abbew, R Laryea, F Sorvor, Y A Poku, N Lorent, D Obiri-Yeboah, L Lynen, L Rigouts","doi":"10.5588/ijtldopen.24.0242","DOIUrl":"10.5588/ijtldopen.24.0242","url":null,"abstract":"Introduction: Non-tuberculous mycobacteria (NTM) are increasingly isolated in individuals with presumed/confirmed pulmonary TB. We aimed to estimate the prevalence and species distribution of NTM among presumed/confirmed drug-resistant TB (DR-TB) individuals and determine NTM isolation predictors.Methods: Sputum samples collected for DR-TB diagnosis and follow-up from 2012 to 2021 in Ghana were retrospectively analysed. Samples were subjected to sputum smear microscopy (SSM) and mycobacterial culture. The MPT64 assay was performed on positive cultures to distinguish between Mycobacterium tuberculosis complex MTBc and NTM. NTM isolates were re-cultured for species identification using GenoType® Mycobacterium CM/AS line-probe assay, polymerase chain reaction, and Sanger sequencing targeting 16S rRNA and rpoB genes. MTBc isolates identified by GenoType underwent spoligotyping. A logistic regression model was used to identify the predictors of NTM isolation.Results: Of the 2,492 samples, 839 (33.7%) tested culture-positive for mycobacteria, with 257 (30.6%) presumed to be NTM. Of these, 53 (23.6%) were identified at the species level, with a predominance of M. intracellulare (66.0%). MPT64 testing missed 18 (3%) MTBc isolates. Logistic regression showed increased odds of NTM isolation in follow-up samples (aOR 2.41, 95% CI 1.46-3.99). NTM species were isolated from 46 patients, with four classified as NTM pulmonary disease.Conclusion: Enhancing our understanding of local NTM epidemiology and improving local diagnostic capabilities can optimise patient management strategies and outcomes.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"1 7","pages":"306-313"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11257093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unit costs and cost-effectiveness of a device to improve TB treatment adherence in China. 中国提高结核病治疗依从性设备的单位成本和成本效益。

IJTLD open Pub Date : 2024-07-01 DOI: 10.5588/ijtldopen.23.0451

S Sweeney, K Fielding, X Liu, J A Thompson, H Dong, S Jiang, Y Zhao, S Huan, A Vassall

{"title":"Unit costs and cost-effectiveness of a device to improve TB treatment adherence in China.","authors":"S Sweeney, K Fielding, X Liu, J A Thompson, H Dong, S Jiang, Y Zhao, S Huan, A Vassall","doi":"10.5588/ijtldopen.23.0451","DOIUrl":"10.5588/ijtldopen.23.0451","url":null,"abstract":"Background: Adherence to TB drugs is crucial for improving treatment outcomes. Digital adherence technologies can improve adherence; however, there is a lack of evidence on cost-effectiveness. This study aimed to explore the cost-effectiveness of medication event reminder monitors (MERM) in China compared with the standard of care, using results from a pragmatic, cluster-randomised superiority trial of an electronic MERM in China.Methods: We collected primary unit cost data from the societal perspective, both at and above the health facility level. We estimated the incremental cost-effectiveness of MERM using a Markov model with a 20-year time horizon; a 3% discount rate was applied to costs and outcomes. We explored uncertainty through a series of sensitivity and scenario analyses.Results: The incremental cost of MERM was $27.22 per patient. Probabilistic sensitivity analysis showed significant uncertainty about the intervention's cost-effectiveness. Changing assumptions around key parameters substantially affected our estimated incremental cost-effectiveness ratio.Conclusions: Although the incremental cost of the MERM box was low, current evidence does not indicate that the intervention would be cost-effective. However, the intervention's cost-effectiveness could improve if implemented as part of a broader strategy, including enhanced patient management.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"1 7","pages":"299-305"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11257087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A survey of the effectiveness of centralized consilia in providing advice on drug-resistant TB. 对中央协调机构就耐药性结核病提供建议的有效性进行调查。

IJTLD open Pub Date : 2024-07-01 DOI: 10.5588/ijtldopen.24.0228

A Vasquez, C Mitnick, A U Nyaruhirira, C-Y Chiang, C R Horsburgh

引用次数: 0

Severe outcomes among adults with TB during COVID-19. COVID-19 期间成人肺结核患者的严重后果。

IJTLD open Pub Date : 2024-07-01 DOI: 10.5588/ijtldopen.24.0220

T Jacobs, E Morden, M Smith, A von Delft, R Kassanjee, V Mudaly, A Boulle, M-A Davies

{"title":"Severe outcomes among adults with TB during COVID-19.","authors":"T Jacobs, E Morden, M Smith, A von Delft, R Kassanjee, V Mudaly, A Boulle, M-A Davies","doi":"10.5588/ijtldopen.24.0220","DOIUrl":"10.5588/ijtldopen.24.0220","url":null,"abstract":"Background: The COVID-19 pandemic prompted strict public health measures to reduce SARS-CoV-2 transmission, potentially interrupting TB programmes in the Western Cape, South Africa.Methods: We conducted a retrospective cohort study, estimating changes in new TB case rates and risk of death during TB-specific admissions within 6 months of TB first evidence, during the pre-pandemic (1 January 2019-26 March 2020) and after the implementation of public health and social measures (PHSM) periods (26 March 2020-30 September 2021), based on PHSM strictness. We used interrupted time series and logistic regression models to adjust for key characteristics.Results: We found an average 22% reduction (95% CI 19-25) in monthly TB cases during the entire PHSM implementation period. Additionally, the risk of death during TB-specific admissions increased, with the adjusted odds ratio ranging across PHSM levels from 1.36 (95% CI 1.17-1.57) on Level 1 to 1.44 (95% CI 1.16-1.79) on Level 2 compared with the pre-pandemic period.Conclusions: There was a decline in the number of diagnosed TB cases and an increased risk of severe outcomes from 26 March 2020 to 30 September 2021 in the Western Cape. TB programme recovery strategies must be prioritised, and TB management programmes must be integrated into future pandemic responses.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"1 7","pages":"292-298"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11257091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Update on IJTLD OPEN: the future is open. 国际顶级域名开放的最新情况：未来是开放的。

IJTLD open Pub Date : 2024-07-01 DOI: 10.5588/ijtldopen.24.0316

H D Blackbourn, G B Migliori

引用次数: 0

Management challenges and outcomes for non-tuberculous mycobacterial pulmonary disease. 非结核分枝杆菌肺病的管理挑战和结果。

IJTLD open Pub Date : 2024-07-01 DOI: 10.5588/ijtldopen.24.0140

J De Man, N Adriaenssens, P Van Bleyenbergh, M Happaerts, E André, I Spriet, L Dupont, N Lorent

引用次数: 0

Screening rates for HIV and diabetes in patients with active TB: results of a nationwide survey in Japan. 活动性肺结核患者的艾滋病和糖尿病筛查率：日本全国性调查的结果。

IJTLD open Pub Date : 2024-07-01 DOI: 10.5588/ijtldopen.24.0282

Y Kimura, Y Sasabuchi, T Jo, Y Hashimoto, R Kumazawa, M Ishimaru, H Matsui, A Yokoyama, G Tanaka, H Yasunaga

引用次数: 0

Prevalence, incidence and determinants of QuantiFERON^TM positivity in South African schoolchildren. 南非学童定量FERONTM阳性的流行率、发病率和决定因素。

IJTLD open Pub Date : 2024-05-01 DOI: 10.5588/ijtldopen.24.0084

J Stewart, N Walker, K Jennings, C Delport, J Nuttall, A K Coussens, R Dyers, D A Jolliffe, J C Y Tang, W D Fraser, R J Wilkinson, L-G Bekker, A R Martineau, K Middelkoop

{"title":"Prevalence, incidence and determinants of QuantiFERONTM positivity in South African schoolchildren.","authors":"J Stewart, N Walker, K Jennings, C Delport, J Nuttall, A K Coussens, R Dyers, D A Jolliffe, J C Y Tang, W D Fraser, R J Wilkinson, L-G Bekker, A R Martineau, K Middelkoop","doi":"10.5588/ijtldopen.24.0084","DOIUrl":"10.5588/ijtldopen.24.0084","url":null,"abstract":"Background: TB control requires the understanding and disruption of TB transmission. We describe prevalence, incidence and risk factors associated with childhood TB infection in Cape Town, South Africa.Methods: We report cross-sectional baseline and prospective incidence data from a large trial among primary school children living in high TB burden communities. Prevalent infection was defined as QuantiFERON™-TB Gold Plus (QFT-Plus) positivity as assessed at baseline. Subsequent conversion to QFT-Plus positivity was measured 3 years later among those QFT-Plus-negative at baseline. Multivariable logistic regression models examined factors associated with TB infection.Results: QuantiFERON-positivity at baseline (prevalence: 22.6%, 95% CI 20.9-24.4), was independently associated with increasing age (aOR 1.24 per additional year, 95% CI 1.15-1.34) and household exposure to TB during the participant's lifetime (aOR 1.87, 95% CI 1.46-2.40). QFT-Plus conversion at year 3 (12.2%, 95% CI 10.5-14.0; annual infection rate: 3.95%) was associated with household exposure to an index TB case (aOR 2.74, 95% CI 1.05-7.18).Conclusion: Rates of QFT-diagnosed TB infection remain high in this population. The strong association with household TB exposure reinforces the importance of contact tracing, preventative treatment and early treatment of infectious disease to reduce community transmission.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"1 5","pages":"206-214"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141636412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0